ÐÓ°ÉÔ­´´

MinervaX, based in Copenhagen, is advancing the biotech field by developing a prophylactic vaccine against Group B Streptococcus (GBS) infections. This focus positions it as a key player in prenatal health, addressing risks of neonatal infections currently managed through screening and antibiotics. By prioritizing vaccine development, MinervaX aims to offer a more effective and less intrusive solution. The company's B2B model, along with backing from investors like EQT Partners and Novo A/S, showcases its potential for medical advancement and commercial success. If successful, MinervaX could revolutionize prenatal care, leading to widespread adoption and significant market impact.